# Michel Kroes

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michel-kroes/

## Facts

| Field | Value |
| --- | --- |
| Citations | 341 |
| Field | Renal Diseases and Glomerulopathies |
| h-index | 8 |
| i10-index | 7 |
| Last Known Institution | Novartis (Switzerland) |
| OpenAlex ID | https://openalex.org/A5077800538 |
| ORCID iD | 0000-0002-1381-9184 |
| Works | 43 |

## Researcher papers

- [Impact of weight change on quality of life in adults with overweight/obesity in the United States: a systematic review](https://scholariq.org/papers/impact-of-weight-change-on-quality-of-life-in-adults-with-overweight-obesity-in/)
- [A Systematic Review of Insulin Adherence Measures in Patients with Diabetes](https://scholariq.org/papers/a-systematic-review-of-insulin-adherence-measures-in-patients-with-diabetes/)
- [Systematic review of the prevalence of psychiatric illness and sleep disturbance as co-morbidities of HIV infection in the UK](https://scholariq.org/papers/systematic-review-of-the-prevalence-of-psychiatric-illness-and-sleep-disturbance/)
- [Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis](https://scholariq.org/papers/second-line-treatments-for-the-management-of-advanced-renal-cell-carcinoma/)
- [Transition to secondary progressive multiple sclerosis: The consequences for patients and healthcare systems, a healthcare professional survey](https://scholariq.org/papers/transition-to-secondary-progressive-multiple-sclerosis-the-consequences-for/)
- [Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK](https://scholariq.org/papers/stick-or-twist-cost-effectiveness-of-siponimod-compared-with-continuing-existing/)
- [The cost–effectiveness of diagnostic cardiac imaging for stable coronary artery disease](https://scholariq.org/papers/the-cost-effectiveness-of-diagnostic-cardiac-imaging-for-stable-coronary-artery/)
- [Second-line single-agent chemotherapy in human epidermal growth factor receptor 2-negative metastatic breast cancer: A systematic review](https://scholariq.org/papers/second-line-single-agent-chemotherapy-in-human-epidermal-growth-factor-receptor/)
- [When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing–remitting multiple sclerosis](https://scholariq.org/papers/when-does-economic-model-type-become-a-decisive-factor-in-health-technology/)
- [Clinical and Humanistic Burden of IgA Nephropathy in Adult Patients](https://scholariq.org/papers/clinical-and-humanistic-burden-of-iga-nephropathy-in-adult-patients/)
- [Diagnosis and treatment in adult patients with C3 glomerulopathy in Japan: a real-world survey](https://scholariq.org/papers/diagnosis-and-treatment-in-adult-patients-with-c3-glomerulopathy-in-japan-a-real/)

## Researcher topics

- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Multiple Sclerosis Research Studies](https://scholariq.org/topics/multiple-sclerosis-research-studies/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)
- [Immunodeficiency and Autoimmune Disorders](https://scholariq.org/topics/immunodeficiency-and-autoimmune-disorders/)

## Researcher university

- [Novartis (Switzerland)](https://scholariq.org/institutions/novartis-switzerland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.